Schrag, D., Dueck, A. C., Naughton, M. J., Niedzwiecki, D., Earle, C., Shaw, J. E., … Venook, A. P. (2015). Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.

Schrag, Deborah, Amylou C. Dueck, Michelle Joy Naughton, Donna Niedzwiecki, Craig Earle, James Edward Shaw, Axel Grothey, Howard S. Hochster, Charles David Blanke, and Alan P. Venook. “Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.

Schrag D, Dueck AC, Naughton MJ, Niedzwiecki D, Earle C, Shaw JE, et al. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.

Schrag, Deborah, et al. “Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405.” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.

Schrag D, Dueck AC, Naughton MJ, Niedzwiecki D, Earle C, Shaw JE, Grothey A, Hochster HS, Blanke CD, Venook AP. Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.